In an insightful interview with Mr. Sanjay Vyas, Executive Vice President, Country Head- India, and Managing Director of Parexel, the transformation of the Indian healthcare sector over the past few years takes centre stage. The discussion primarily revolves around clinical trials, their significance, and the factors contributing to India’s emergence as a hub for such trials.
A clinical trial, as explained by Mr. Vyas, is the rigorous process through which drugs and therapies undergo testing, beginning with animal trials, and progressing to patient trials to determine safety and efficacy. This complex journey can span 3 to 15 years before a drug hits the market.
India’s ascendancy as a clinical trial hub is attributed to several factors. Regulatory reforms in 2019 aligned India’s clinical trial regulations with global standards, enhancing ethical compliance. Additionally, the COVID-19 pandemic catalysed the industry by highlighting the importance of clinical trials, making it a widespread topic of discussion.
Key strengths contributing to India’s success in clinical trials include its robust healthcare ecosystem, state-of-the-art infrastructure, and a well-educated workforce. India now produces the highest number of pharmacy graduates and physicians globally, along with expertise in biostatistics, programming, and data management. Collaboration between industry, academia, and the government has further driven progress. Initiatives promoting investment in biotech have shifted the focus from generics to new chemical entities, nurturing innovation.
One of the unique features highlighted in the interview is Parexel’s patient-centric approach. The organization ensures that every decision and process change considers the impact on patients. To make clinical trials more patient-friendly, Parexel established a Patient Innovation Centre and a Patient Advisory Council. The patients who have been through clinical trials provide insights into challenges they faced, including socioeconomic and cultural barriers. This feedback is integrated into protocols, making them more patient-centric. The Patient Advisory Council also educates patients in relevant therapeutic areas, creating advocates for the process.
The interview showcases how Parexel’s comprehensive approach, coupled with favourable regulations and a patient-centric focus, has contributed to India’s prominence in clinical trials. India’s healthcare landscape has transformed, not only attracting trials but also ensuring that patients can access therapies with greater ease and understanding. For a more in-depth exploration of these insights, we strongly encourage you to watch the complete interview.
